PAX Debuts The Oxblood Edit, a Limited Edition Collection Inspired by Fall’s Richest Color
8.9.2026 15:00:00 CEST | Business Wire | Press Release
Today PAX, a pioneering global cannabis brand, introduces The Oxblood Edit, an ultra-limited release bringing one of fall’s defining colors to three of the brand’s signature devices: PAX FOUR, PAX MINI and ERA GO. Deep, distinctive and designed to be coveted, Oxblood transforms the PAX lineup through a rich burgundy finish inspired by the worlds of fashion, interiors and industrial design. The limited collection is available beginning today at pax.com and select retailers, while supplies last.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908330141/en/
The Oxblood Edit: bringing timeless style, seasonal color, and elevated design to three of the brand's signature devices.
Long associated with craftsmanship and enduring style, oxblood has reemerged across fashion, footwear, accessories and interiors as consumers gravitate toward richer palettes, timeless materials and elevated essentials. For PAX, the color is less about chasing a seasonal trend than expressing a nearly two-decade design philosophy that technology should perform beautifully, feel considered in every detail and be designed to live with you.
“Great design has always been fundamental to PAX. Not simply how our products look, but how they feel, function and fit into people’s lives,” said Chris Ahern, CEO of PAX. “With The Oxblood Edit, we wanted to create something that feels both distinctly of-the-moment and connected to our enduring heritage. It takes an everyday object and makes it more personal, while still beautifully made, thoughtfully designed and worthy of the rituals that shape modern living.”
The collection brings Oxblood to PAX’s newest and most powerful dry herb device, PAX FOUR, recently named the “best loose-leaf vaporizer on the market” by WIRED; the compact and approachable PAX MINI; and ERA GO, the sleek, pocket-sized battery for PAX ERA pods.
PAX FOUR features high-output hybrid heating engineered to produce 50% more vapor and heat up faster than any previous PAX dry herb device. Four preset heat modes with patented temperature control allow consumers to tailor each session, from quick and high-impact to longer and more sustained. PAX MINI offers a simple introduction to dry herb vaporization through a compact design and single-button interface, while ERA GO pairs effortless portability with PAX’s high-performance pod system.
Across the portfolio, that focus on design is matched by a commitment to creating better ways to experience cannabis. Unlike smoking, PAX dry herb devices heat cannabis without burning it. Recent PAX research found that vaporizing cannabis reduced exposure to harmful combustion byproducts—including benzene, formaldehyde and acetaldehyde—by up to 99% compared with smoking a preroll. More information is available at pax.com/science.
To celebrate The Oxblood Edit, PAX is bringing the collection to life through a series of cultural moments spanning fashion, art and design. During New York Fashion Week, PAX will partner with FANG NYC for its Fall 2026 runway show, bringing Oxblood into one of fashion’s most influential weeks. On September 22, Oxblood will take over a Lower East Side gallery for one night only, bringing together a curated group of artists, makers and brands, each offering their own interpretation of the season’s defining shade. The evening will feature art by Lee Smith, food by House of Flavor, a wine tasting with Amari Collins and a Leisure Golf & Skate pop-up—all drenched in the rich, provocative world of Oxblood, with more surprises to come.
The Oxblood Edit is available beginning September 8, 2026, exclusively at pax.com and in select retailers. PAX devices are also available year-round in Onyx and Greenstone.
PAX is a leading global cannabis brand redefining the role cannabis plays in modern life. Through thoughtful design, pioneering innovation and scientific rigor, PAX creates products that integrate seamlessly into life's most meaningful moments—helping consumers enjoy the plant with greater intention, presence and appreciation. PAX is committed to making a positive impact and is certified Plastic Negative across all product lines by rePurpose Global, removing twice as much plastic from nature as is used in PAX products.
© 2026 PAX Labs, Inc. All Rights Reserved. PAX, X, and ERA are trademarks of PAX Labs, Inc. Patents and trademarks: pax.com/IP. NOT FOR SALE TO MINORS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260908330141/en/
Contacts
MEDIA CONTACT:
press@pax.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom